Voyager Therapeutics (VYGR) Q2 2024 earnings summary

Executive summary

• Achieved key milestones in Q2 2024, including dosing first volunteers in the phase IA trial of anti-Tau antibody VY7523 for Alzheimer's disease and advancing multiple gene therapy programs targeting CNS diseases.

• Advanced clinical and preclinical programs, with IND-enabling work for SOD1 ALS gene therapy and candidate selection for GBA1 and FA programs, triggering milestone payments from Neurocrine.

• Strategic collaborations with Neurocrine, Novartis, and Alexion provide significant non-dilutive funding and milestone opportunities.

• Ended Q2 with $371M in cash, cash equivalents, and marketable securities, providing runway through multiple clinical data readouts into 2027.

• Appointed Nathan Jorgensen, Ph.D., as Chief Financial Officer, strengthening the leadership team.

Financial highlights

• Q2 2024 collaboration revenue was $29.6M, up from $4.9M in Q2 2023, driven by milestone payments and ongoing partnerships.

• Q2 2024 net loss was $10.1M, improved from $22.2M net loss in Q2 2023, due to higher collaboration revenue.

• R&D expenses increased to $34.5M in Q2 2024 from $22.0M in Q2 2023, reflecting higher facility, personnel, and program costs, including $2.5M lease impairment and $0.5M relocation costs.

• G&A expenses rose to $10.2M in Q2 2024 from $8.3M in Q2 2023, with $1.3M in non-recurring items.

• Net cash provided by operating activities was $27.2M for the first half of 2024, with $113.4M raised from financing activities, including a $93.5M public offering.

Outlook and guidance

• Cash runway expected to support operations and planned R&D through multiple data readouts into 2027.

• Top-line safety and PK data for anti-Tau antibody VY7523 expected in H1 2025; MAD trial in early Alzheimer's planned for 2025, with initial Tau PET imaging data in H2 2026.

• IND filings for SOD1 ALS, GBA1, and FA gene therapy programs anticipated in 2025; IND for Tau silencing gene therapy expected in 2026.

• Anticipates continued increase in R&D and G&A expenses as programs advance and headcount grows.